Background. There is considerable variability in the inter-patient response to norepinephrine. Pharmacokinetic studies of dopamine infusion in volunteers and in patients have also shown large variability. The purpose of this study was to define the pharmacokinetics of norepinephrine in septic shock and trauma patients.
Norepinephrine infusion is used routinely to support arterial pressure and organ function in critically ill patients. Clinical experience suggests there is considerable inter-patient variability in response to norepinephrine infusions. Multiple factors, for example age, renal function, hepatic function, may influence the response to norepinephrine. Free radicals, produced in large quantity in septic shock and trauma, may interact with catecholamines and decrease their concentration. 1 Thus, the pressor response, and other effects such as the modulation of cytokines release, 2 3 may vary with the pharmacokinetics of norepinephrine. Few clinical studies have addressed the variability of the effects of norepinephrine. [4] [5] [6] Studies with dopamine in volunteers 7 and in patients, 6 and with dobutamine in critically ill surgical patients 8 have shown both intra-and inter-subject variability in infusion rate and serum concentrations. This makes standard pharmacokinetic modelling of less utility than for other drugs. Similarly, norepinephrine plasma concentrations were poorly related to the infusion rate in patients with head trauma. 6 Norepinephrine is rapidly eliminated from the blood (half-life is 2-2.5 min). However, when norepinephrine is administered at a dose 10 3 -10 6 times higher than the natural spill-over (the fraction of synthesis not metabolized locally), it is conceivable that the metabolic pathways become saturated, leading to non-linear pharmacokinetics. Norepinephrine's pharmacodynamic effect depends on vascular tone, which has been reported to be impaired in trauma 9 and septic patients. 10 Therefore, the variability in the clinical response to norepinephrine may depend on both pharmacokinetic and pharmacodynamic factors.
The purpose of this study was to determine the pharmacokinetics and pharmacodynamics of norepinephrine in patients with septic shock and in trauma patients. Our hypothesis was that a pharmacokinetic-pharmacodynamic (PK-PD) model of norepinephrine could be used to define doses of the drug that would be required to obtain specific plasma concentrations in septic shock and in trauma. Similarly, we expected that one or several simple covariates might explain part of the variability in PK-PD.
Patients and methods
After Ethics Committee approval and written informed consent, 23 patients (12 septic shock patients and 11 trauma patients) requiring an infusion of norepinephrine to support arterial pressure were enrolled. These patients were all sedated with midazolam and sufentanil infused at a constant rate, and mechanically ventilated. Patients were included within 24 h of starting catecholamines. Exclusion criteria were as follows: (1) age under 18 yr; (2) pregnancy; (3) history of coronary disease, cardiac failure, cardiac rhythm trouble. The criteria for inclusion in the group with sepsis syndrome have been reported previously 11 and include fever (temperature >38.3 C) or hypothermia (temperature <35.5 C), tachycardia (>90 beats min À1 ), tachypnoea (>20 breaths min À1 ), clinical suspicion of infection, and at least one of the following: hypoxaemia (Pa o 2 <9.6 kPa on room air or Pa o 2 (mm Hg)/Fi o 2 <280), oliguria (urine output <30 ml or 0.5 ml kg À1 BW for 1 h), unexplained metabolic acidosis (or an elevated plasma lactate level), or a recent change in mental status. Multiple trauma patients were defined by an Injury Severity Score (ISS) >16.
On admission to ICU, monitoring included heart rate, invasive arterial pressure, oxygen saturation, ventilatory frequency, and temperature. Biologic variables (hepatic enzyme, renal function, haemoglobin, haemostasis) were also recorded.
We only considered septic shock and trauma patients that required a norepinephrine infusion within their first day, and patients were enrolled within 24 h of starting norepinephrine. Standards of care were not modified by the study. All patients were already treated with norepinephrine, which was administered through a central venous catheter. The patients were not receiving any other drugs. After an initial period of 60 min, the norepinephrine dose was increased by three successive steps of 0.1 mg kg À1 min À1 , at 15-min intervals (with a 20% maximum allowed increase in arterial pressure). The dose was then reduced to the initial level. Clinical and biological variables were measured before changing the norepinephrine rate, at t30 s (on the steep part of the concentration-time curve), t13 min, t15 min (when steady concentration was approached) for each of the three steps and at the end of the study. Additional sampling was performed in nine patients (five trauma and four septic) at t+30 s, t+1 min, t+2 min, t+5 min, t+10 min, and t+15 min after the dose was reset to its initial value.
Sampling and assay
Blood (5 ml) was sampled in tubes containing EGTA [ethylene glycol bis(2-aminoethyl ether)-N,N,N 0 N 0 -tetra acetic acid] and gluthatione. The tubes were immediately centrifuged at 4 C and plasma samples were stored at À20 C before assay. Norepinephrine concentration was measured, in plasma, using HPLC with coulometric detection. 12 13 Briefly, after the addition of the internal standard (dihydroxybenzoic acid, DHBA), the samples were extracted on alumina and 50 ml of the acidic extract was injected manually. The mobile phase consisted of a 90/10 (vol/vol) mixture of 0.03 M citric acid, 0.015 M Na 2 HPO 4 buffer (pH 5.5) containing sodium octane-sulfonic acid 0.7 g litre À1 and methanol. The mobile phase was set at a flow rate of 1 ml min À1 . The detector was a Coulochem (ESA model 5100A, Eurosep Cergy, St Christophe, France) with a 5011 analytical cell set at +0.03 and 0.30 V.
Statistical analysis
Normality was checked for continuous data using the Shapiro-Wilk test. Patient characteristics were compared between the two groups using the Student's t-test for continuous data and the x 2 test for dichotomous data. An initial estimation of individual norepinephrine clearance was made by calculating the steady-state non-parametric clearance just before the first step increase in dosing (CL=dose/concentration). Data are reported as median (range) or mean (SD) where appropriate. Kinetic (concentration vs time) data and dynamic (mean arterial pressure vs time) data were fitted in a two-stage manner using mixed effect modelling with the software NONMEM (Version V, level 1).
14 Kinetics were modelled using a one-compartment model with first order elimination. In this case, the half-life (T 1/2 ) is directly proportional to the volume of distribution (V) and negatively proportional to clearance (T 1/2 =0.693 V/Cl). We selected the one-compartment model after comparison with a twocompartment model using the Akaike criterion (AIC). 15 A random effect parameter was associated with clearance and volume to account for inter-individual variability. In a first step, Bayesian estimates of parameters (i.e. clearance and volume) obtained with a first NONMEM run were regressed on potential covariates, that is group, gender, BW, creatinine clearance, prothrombin time, and SAPS II score. 16 In a second step, a full model including the most pertinent covariates was constructed and reduced models were successively fitted. In addition, we compared individual clearances calculated with the non-parametric method and the NONMEM Bayesian estimates.
MAP vs norepinephrine concentration was modelled using the classic Emax model:
þ C g , where MAP 0 is the estimated basal arterial pressure in the absence of norepinephrine, MAP MAX is the theoretical maximum increase in MAP if norepinephrine was infused at an infinite dosage (in this case, the resulting maximum MAP would be MAP 0 +MAP MAX ), C is NOR concentration, EC 50 is the norepinephrine concentration leading to half MAP MAX and g is the Hill exponent. A random effect parameter was associated with MAP 0 , MAP MAX , EC 50 , and g to account for inter-individual variability. The PD model was fitted using the individual Bayesian estimates of PK parameters obtained with the most pertinent PK model, and the effect was considered to have occurred in the central compartment. The same stepwise procedure from the kinetic analysis was used to determine the best model according to potential covariates. For both PK and PD modelling we used the conditional estimation method with interaction and a heteroscedastic error model. The log likelihood ratio test was used for assessing the statistical significance between nested models. The inter-individual variability [95% confidence interval (95% CI) of the structural parameters] was assessed by log-likelihood profiling.
Results
Groups were similar in terms of gender, weight, and severity assessed with the (Simplified Acute Physiology Score II) 17 SAPS II score ( Table 1 ). The septic group was significantly older and had a lower creatinine clearance than the trauma group ( Table 1) . The baseline dose received by the patients varied from 0.093 to 6.3 mg kg À1 min À1 with a median of 1.8 mg kg À1 min À1 . The initial observed norepinephrine concentration ranged from 0.99 to 186 mg ml À1 with a median of 16.2 mg ml À1 . No direct correlation between dose and concentration was observed. The initial regression step between Bayesian estimates of clearance obtained with the initial fitting and potential covariates showed that norepinephrine clearance was inversely related to SAPS II (Fig. 1) . A full model incorporating group (trauma/septic), body weight and SAPS II score as predictive covariates for clearance was then constructed and successive reduced models were tested against this model. The best-reduced model was the model incorporating only the SAPS II score, confirming the prediction made by the initial regression step (Tables 2 and 3 and Fig. 2) . None of the other covariates tested for inclusion in the model showed any statistically significant influence on clearance. Similarly, a model incorporating these previously mentioned potential covariates was built for volume of distribution prediction. However, none of these covariates showed any significant improvement of fitting. The terminal half-life varied from 2.0 min in the least severely ill patients (SAPS II=20) to 6.8 min in the most severe (SAPS II=66) ( Table 3 ). The correlation between the two methods (non-parametric and Bayesian estimates) used for calculating clearance showed excellent agreement (Fig. 3) . The assumption of linear kinetics is clearly supported by this correlation, and by the fact that fit was equally good at low and at high concentrations when the dose was increased (Fig. 2) . The overall basal MAP (MAP 0 ) was 71 (11) mm Hg. The pharmacodynamic data (MAP vs norepinephrine concentration and time) were adequately fitted by the E max model. Random effects were significantly associated only with MAP 0 and MAP MAX . Estimates of fixed effect (structural) parameters and their associated random effect parameters are listed in Table 3 . No covariate (SAPS II score, gender, group, age, BW) showed any significant influence on the fitting. Individual Bayesian parameter estimates are displayed in Table 4 .
Discussion
We have studied the potential effect of several covariates on the pharmacokinetics and on the pharmacodynamics of norepinephrine, in patients with severe trauma or septic shock, using mixed effect modelling with NONMEM. The main findings of the present study were: (1) norepinephrine kinetics were best described using a onecompartment linear model and norepinephrine clearance was negatively related to SAPS II score taken as a global indicator of illness severity, (2) MAP was related to norepinephrine plasma concentration but no covariate was able to describe the observed inter-individual variability.
Norepinephrine is metabolized by two major intracellular enzymes. 18 The redundancy in the metabolizing enzymes and transporters may explain why saturation kinetics are not seen even at the concentrations achieved by exogenous administration. It has been shown, in dogs, that exogenously administered norepinephrine was eliminated primarily by the liver. 19 Additional elimination also occurs in the kidney and capillary walls, especially in lungs. Norepinephrine clearance is, therefore, related to cardiac output. 20 In our study, norepinephrine kinetics were best fitted using a linear one-compartment model with first order elimination. Johnston and colleagues 6 recently showed that norepinephrine pharmacokinetics are predictable in patients with head trauma. These authors found that norepinephrine plasma levels were correlated with norepinephrine infusion rates, without any significant influence on plasma clearance. These data were consistent with single-compartment, firstorder kinetics for norepinephrine. The norepinephrine pharmacodynamics were however unpredictable. No correlation was found between norepinephrine plasma levels and http://bja.oxfordjournals.org changes in MAP. In a study describing the pharmacokinetics of epinephrine and norepinephrine in patients following cardiac arrest, Prengel described two-compartment, linear kinetics for epinephrine. 21 In contrast, norepinephrine kinetics exhibited a single exponential decay. The single compartment kinetics occurred at concentrations similar to those measured in our study. In critically ill children, Fisher and colleagues 22 suggested linear pharmacokinetics for epinephrine. In the present study, even in patients with impaired metabolic function, saturation kinetics were not observed and the correlation between the two methods used for calculating clearance (non-parametric estimation and compartmental analysis) showed excellent agreement.
Ensinger and colleagues, 23 in healthy volunteers, showed a linear relationship between norepinephrine dosing and plasma concentrations. In head-injured patients, Johnston and co-workers described a linear relationship between norepinephrine infusion rate and plasma concentration. 6 These authors failed to demonstrate any clear relationship between norepinephrine infusion rate and clearance. We did not observe any relationship between norepinephrine dosing and concentrations because of major inter-individual variability both in volume and clearance. Thus, we have looked for covariates to explain this variability. Only the SAPS II score was significantly inversely correlated with clearance. The volume of distribution did not correlate with any of the potential covariates tested. The immediate consequence of this decreased body clearance with increased severity score was an increased terminal half-life in the most severely ill patients. Nevertheless, differences in SAPS II score could not exclusively explain the large variability in clearance. Indeed, with constant dose norepinephrine infusion, plasma concentration could exhibit only a 3-fold variation, depending on the patient's severity scaled on the SAPS II score. Therefore, the residual variability independent of the patient's SAPS II score remains to be explained.
Previous pharmacokinetic studies with catecholamines have found similar variability. With dopamine, in volunteers, 5 there was both intra-and inter-subject variability in infusion rate and resulting serum concentrations. MacGregor and colleagues 7 found that dopamine dose based on BW did not yield consistent, predictable plasma concentrations in a population of healthy male subjects. Interestingly, Johnston and co-workers, 6 reported a clear relation between dopamine infusion rate and clearance, thus suggesting either non-linear kinetics for dopamine or that increasing the dose increases the cardiac output and therefore total body clearance. Other studies have reported a wide variability with dobutamine 8 in critically ill surgical patients, making standard pharmacokinetic modelling of less utility than for other drugs, and that dopamine clearance is lower in critically ill patients and has a large interindividual variation. 24 We found that the only variable that significantly influenced norepinephrine clearance was the severity of illness.
The changes in mean arterial pressure adequately fitted an E max model incorporating the individual kinetic parameters estimated at the first stage. The population estimate of EC 50 , was 70 mg ml À1 with a wide inter-individual variability (the Table 4 Individual patient characteristics and Bayesian estimates of kinetic and dynamic parameters in the two groups. Group S, septic shock, T, trauma, PT, prothrombin time, CL, total body clearance, V, volume of distribution, T 1/2 , terminal half-life, Clearance non-parametric, clearance measured as the ratio between the infusion rate and the concentration measured just before the first increase in dosing 95% CI, 62-420 mg ml À1 ). The absence of a single covariate to explain this variability, is likely to be due to the small number of patients studied, leading to a lack of power of our study. Differing effects of the severity illness on pharmacokinetics and pharmacodynamics may explain these results. Indeed, the most severely ill patients had a lower clearance and needed less drug to achieve a predetermined concentration. However, we anticipated a shift to the right of the dose-effect curve in these patients with the most severe illness. This lack of relationship between infusion rate, plasma concentration, and haemodynamic parameters has been reported previously 6 for both dopamine and norepinephrine. Impaired vascular reactivity had been shown in trauma 9 and in septic shock 10 patients. In trauma, impaired pressor sensitivity to catecholamines has been demonstrated in animals. 25 MacArthur and colleagues 1 have previously shown that inactivation of catecholamines by superoxide anions contributes to the loss of vascular reactivity to norepinephrine and the subsequent hypotension that develops in Gram-negative endotoxic shock. Recent studies have related this vasopressor dependency to abnormal adrenocortical function observed in inflammatory consequences of septic 26 and hemorrhagic shock. 27 The intensity of this is considered proportional to the severity of the shock. Our study did not significantly relate any factors to this hyporeactivity. Indeed, in healthy volunteers, Ensinger and co-workers 23 also failed to show a relationship between norepinephrine concentration and haemodynamic variables.
In conclusion, an inverse relationship between norepinephrine clearance and severity illness was found. We failed to find any clear factor explaining the pharmacodynamic variability. This suggests the primary factor of variability in dose is pharmacokinetic.
